Virios Therapeutics Announces Initial FDA Feedback On Proposed IMC-1 Phase 3 Program For Treatment of Fibromyalgia; Says Final Toxicology Results To Be Submitted To FDA In
May 2023
Virios Therapeutics Announces Initial FDA Feedback On Proposed IMC-1 Phase 3 Program For Treatment o
Commentaires